

**RESOLUTION NOTICE OF
THE 101ST ANNUAL GENERAL MEETING OF SHAREHOLDERS OF
SANTEN PHARMACEUTICAL CO., LTD.**

Dear Shareholder:

We hereby inform you of the reports and the resolutions that were made, as set forth below, in the 101st Annual General Meeting of Shareholders of the Company that was held today.

Reports:

1. Business Report, Consolidated Financial Statements and Financial Statements for the 101st Business Term (April 1, 2012 to March 31, 2013)
2. Independent Auditor Report and Corporate Auditor Report on the Consolidated Financial Statements for the 101st Business Term (April 1, 2012 to March 31, 2013)

As regards the items set forth above, the contents thereof were reported.

Resolved Items:

Proposal No. 1: Appropriation of Surplus

This item was approved as per the original proposal. The term-end dividends of profits were resolved to be JPY 50 per share. Consequently, the total dividends for the annual business term, including the interim dividends previously distributed are JPY 100 per share.

Proposal No. 2: Appointment of Five (5) Directors

As regards this item, Akira Kurokawa, Sadatoshi Furukado, Noboru Kotani, Akihiro Okumura and Takayuki Katayama were appointed as per the original proposal; each of them assumed their respective offices.

Noboru Kotani, Akihiro Okumura and Takayuki Katayama are Outside Directors.

Proposal No. 3: Grant of Retirement Allowance to the Retiring Directors and Payment of Retirement Allowance upon the Abolition of the Retirement Benefit Program for Directors

This item was approved as per the original proposal. It was resolved that the Company will grant, within the maximum aggregate amount of JPY 50 million, as prescribed under the regulations of the Company, a retirement allowance to Toshiaki Nishihata, the retiring director.

TRANSLATION/FOR REFERENCE PURPOSE ONLY

It was approved that the specific amount, date and procedure of the grant be entrusted to the determination of the Board of Directors.

It was also resolved that, upon the abolition of the retirement benefit program for directors, the Company will pay, within the maximum aggregate amount of JPY 210 million, as prescribed under the regulations of the Company, a retirement allowance to Directors Akira Kurokawa and Sadatoshi Furukado. While the date of payment shall be made upon their retirement, it was approved that the specific amount and procedure of payment be entrusted to the determination of the Board of Directors.

Proposal No. 4: Grant of Rights to Subscribe for New Shares as Stock Options to Directors as Stock-Linked Remuneration

This item was approved as per the original proposal. It was resolved that the Company grant to the Directors (excluding the Outside Directors) rights to subscribe for new shares as stock options as stock-linked remuneration of not more than JPY 160 million per year.

Yours very truly,

Akira Kurokawa
President & CEO
SANTEN PHARMACEUTICAL CO., LTD.
9-19, Shimoshinjo 3-chome, Higashiyodogawa-ku, Osaka, Japan

TRANSLATION/FOR REFERENCE PURPOSE ONLY

ANNOUNCEMENT

At the Board of Directors meeting, which was held after the close of this Annual General Meeting of Shareholders, Akira Kurokawa was appointed as President and CEO. He assumed the said offices.

As a result thereof, the Directors, Corporate Auditors and Corporate Officers of the Company shall be as follows:

Directors and Corporate Auditors

Akira Kurokawa	President and CEO
Sadatoshi Furukado	Director, Executive Corporate Officer, Japan Business and Human Resources Development, Head of Sales and Marketing Division, Prescription Pharmaceuticals
Noboru Kotani *	Director
Akihiro Okumura *	Director
Takayuki Katayama *	Director
Yoshihiro Noutsuka	Standing Corporate Auditor
Yasuo Sato**	Corporate Auditor
Yasuaki Tsuchiya**	Corporate Auditor
Yutaka Mizuno**	Corporate Auditor

* Outside Directors and are Independent Officers (as set forth under Article 436-2, Paragraph 1 of the Securities Listing Regulations of the Tokyo Stock Exchange, Inc. and Article 7, Paragraph 1 of the Regulations on Codes of Corporate Conduct of the Osaka Securities Exchange; hereinafter, the same classification shall apply.)

**Outside Corporate Auditors and are Independent Officers.

TRANSLATION/FOR REFERENCE PURPOSE ONLY

Corporate Officers (excluding Corporate Officers who are also Members of the Board)

Masamichi Sato	Senior Corporate Officer Head of Santen European Group President of Santen Holdings EU B.V.
Jyrki Liljeroos	Corporate Officer President of Santen Oy
Kenji Morishima	Corporate Officer Head of Human Resources Development and CSR Division
Akihiro Tsujimura	Corporate Officer Head of Asia Division
Atsutoshi Ota	Corporate Officer Head of Product Supply Division
Akio Kimura	Corporate Officer Head of Quality Compliance Division
Takeshi Ito	Corporate Officer Head of Prescription Pharmaceuticals Sales Dept., Sales and Marketing Division, Prescription Pharmaceuticals
Kazuo Koshiji	Corporate Officer Head of Finance and Administration Division
Takashi Kaneko, M.D. Ph.D.	Corporate Officer Deputy Head of Research and Development Division
Naveed Shams, M.D. Ph.D.	Corporate Officer Chief Scientific Officer President & CEO of Santen Inc.

End.